PRA Health Sciences Inc (NASDAQ:PRAH) Shares Purchased by Parallel Advisors LLC

Parallel Advisors LLC lifted its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 33.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,409 shares of the medical research company’s stock after purchasing an additional 605 shares during the quarter. Parallel Advisors LLC’s holdings in PRA Health Sciences were worth $239,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System boosted its position in shares of PRA Health Sciences by 1.1% during the second quarter. State Board of Administration of Florida Retirement System now owns 83,357 shares of the medical research company’s stock worth $8,265,000 after buying an additional 920 shares during the period. Swiss National Bank boosted its position in shares of PRA Health Sciences by 2.9% during the second quarter. Swiss National Bank now owns 109,758 shares of the medical research company’s stock worth $10,883,000 after buying an additional 3,100 shares during the period. Envestnet Asset Management Inc. boosted its position in shares of PRA Health Sciences by 1.6% during the second quarter. Envestnet Asset Management Inc. now owns 9,536 shares of the medical research company’s stock worth $945,000 after buying an additional 150 shares during the period. Stephens Investment Management Group LLC boosted its position in shares of PRA Health Sciences by 1.5% during the second quarter. Stephens Investment Management Group LLC now owns 428,661 shares of the medical research company’s stock worth $42,502,000 after buying an additional 6,429 shares during the period. Finally, Executive Wealth Management LLC boosted its position in shares of PRA Health Sciences by 15.9% during the second quarter. Executive Wealth Management LLC now owns 11,030 shares of the medical research company’s stock worth $1,094,000 after buying an additional 1,510 shares during the period. 95.34% of the stock is owned by hedge funds and other institutional investors.

PRAH has been the subject of several research analyst reports. BidaskClub upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, July 24th. Leerink Swann initiated coverage on PRA Health Sciences in a research report on Tuesday, July 2nd. They set a “market perform” rating and a $105.00 price target for the company. Mizuho set a $100.00 target price on PRA Health Sciences and gave the company a “hold” rating in a report on Friday, May 3rd. Finally, Svb Leerink reiterated a “market perform” rating on shares of PRA Health Sciences in a report on Tuesday, July 2nd. Eight investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. PRA Health Sciences currently has a consensus rating of “Hold” and an average price target of $113.40.

NASDAQ:PRAH traded down $0.23 during midday trading on Friday, reaching $97.49. The company had a trading volume of 37,063 shares, compared to its average volume of 643,211. The firm has a market capitalization of $6.40 billion, a price-to-earnings ratio of 24.81, a PEG ratio of 1.31 and a beta of 1.12. The stock’s fifty day simple moving average is $98.22 and its 200-day simple moving average is $99.73. PRA Health Sciences Inc has a 12-month low of $82.12 and a 12-month high of $121.98. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 1.11.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, July 31st. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.11. The firm had revenue of $763.31 million during the quarter, compared to analyst estimates of $764.95 million. PRA Health Sciences had a return on equity of 26.64% and a net margin of 5.39%. PRA Health Sciences’s revenue was up 5.6% compared to the same quarter last year. During the same period last year, the business posted $1.00 earnings per share. As a group, sell-side analysts expect that PRA Health Sciences Inc will post 4.63 EPS for the current year.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: What strategies should day traders use to execute a trade?

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.